share_log

Citigroup Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $351

Benzinga ·  Mar 21 18:41

Citigroup analyst David Lebovitz maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $338 to $351.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 390
Write a comment